drugset
drugset / Trial / NCT04476953

COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation

NCT04476953 ↗

Phase 2 Active not recruiting 80 enrolled Mayo Clinic
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to test whether Fisetin, a senolytic drug, can assist in preventing an increase in the disease's progression and alleviate complications of coronavirus due to an excessive inflammatory reaction.

Timeline

Start
2020-08-03
Primary completion
2026-09
Completion
2026-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Fisetin Small molecule 20 mg/kg Oral

Indications

COVID-19